vs
Side-by-side financial comparison of CG Oncology, Inc. (CGON) and ClearSign Technologies Corp (CLIR). Click either name above to swap in a different company.
ClearSign Technologies Corp is the larger business by last-quarter revenue ($3.7M vs $2.3M, roughly 1.6× CG Oncology, Inc.). ClearSign Technologies Corp runs the higher net margin — -8.5% vs -1779.0%, a 1770.6% gap on every dollar of revenue. On growth, ClearSign Technologies Corp posted the faster year-over-year revenue change (522.2% vs 409.2%).
CG Oncology, Inc. is a clinical-stage biotechnology company focused on developing innovative targeted immunotherapies for urological cancers including non-muscle invasive bladder cancer. It primarily operates in the U.S. market, advancing pipeline candidates to address unmet medical needs for patients with limited treatment options.
ClearSign Technologies Corporation (ClearSign) is a United States-based company that develops emission-control technology.
CGON vs CLIR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.3M | $3.7M |
| Net Profit | $-41.3M | $-311.0K |
| Gross Margin | — | 21.9% |
| Operating Margin | -2097.3% | -22.5% |
| Net Margin | -1779.0% | -8.5% |
| Revenue YoY | 409.2% | 522.2% |
| Net Profit YoY | -29.9% | 73.3% |
| EPS (diluted) | $-0.52 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.3M | $3.7M | ||
| Q3 25 | $1.7M | $1.0M | ||
| Q2 25 | $0 | $133.0K | ||
| Q1 25 | — | $401.0K | ||
| Q4 24 | $456.0K | $590.0K | ||
| Q3 24 | — | $1.9M | ||
| Q2 24 | — | $45.0K | ||
| Q1 24 | $529.0K | $1.1M |
| Q4 25 | $-41.3M | $-311.0K | ||
| Q3 25 | $-43.8M | $-1.4M | ||
| Q2 25 | $-41.4M | $-1.7M | ||
| Q1 25 | — | $-2.1M | ||
| Q4 24 | $-31.8M | $-1.2M | ||
| Q3 24 | — | $-1.2M | ||
| Q2 24 | — | $-1.9M | ||
| Q1 24 | $-16.9M | $-1.1M |
| Q4 25 | — | 21.9% | ||
| Q3 25 | — | 35.8% | ||
| Q2 25 | — | 41.4% | ||
| Q1 25 | — | 48.9% | ||
| Q4 24 | — | 14.9% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 93.3% | ||
| Q1 24 | — | 39.7% |
| Q4 25 | -2097.3% | -22.5% | ||
| Q3 25 | -3069.0% | -170.1% | ||
| Q2 25 | — | -1382.0% | ||
| Q1 25 | — | -562.8% | ||
| Q4 24 | -8344.1% | -282.4% | ||
| Q3 24 | — | -77.1% | ||
| Q2 24 | — | -4748.9% | ||
| Q1 24 | -4247.4% | -113.6% |
| Q4 25 | -1779.0% | -8.5% | ||
| Q3 25 | -2629.5% | -138.9% | ||
| Q2 25 | — | -1263.2% | ||
| Q1 25 | — | -517.7% | ||
| Q4 24 | -6973.7% | -197.3% | ||
| Q3 24 | — | -62.1% | ||
| Q2 24 | — | -4160.0% | ||
| Q1 24 | -3200.8% | -100.5% |
| Q4 25 | $-0.52 | $-0.06 | ||
| Q3 25 | $-0.57 | $-0.26 | ||
| Q2 25 | $-0.54 | $-0.30 | ||
| Q1 25 | — | $-0.37 | ||
| Q4 24 | $-0.47 | $-0.18 | ||
| Q3 24 | — | $-0.20 | ||
| Q2 24 | — | $-0.40 | ||
| Q1 24 | $-0.36 | $-0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $742.2M | $9.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $752.6M | $9.5M |
| Total Assets | $791.6M | $12.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $742.2M | $9.2M | ||
| Q3 25 | $680.3M | $10.5M | ||
| Q2 25 | $661.1M | $12.3M | ||
| Q1 25 | — | $12.9M | ||
| Q4 24 | $742.0M | $14.0M | ||
| Q3 24 | — | $14.5M | ||
| Q2 24 | — | $16.0M | ||
| Q1 24 | $566.5M | $4.6M |
| Q4 25 | $752.6M | $9.5M | ||
| Q3 25 | $687.6M | $9.1M | ||
| Q2 25 | $670.4M | $10.4M | ||
| Q1 25 | — | $12.0M | ||
| Q4 24 | $733.4M | $13.8M | ||
| Q3 24 | — | $14.8M | ||
| Q2 24 | — | $15.9M | ||
| Q1 24 | $568.9M | $4.5M |
| Q4 25 | $791.6M | $12.2M | ||
| Q3 25 | $729.9M | $12.7M | ||
| Q2 25 | $701.4M | $14.2M | ||
| Q1 25 | — | $14.5M | ||
| Q4 24 | $754.8M | $16.3M | ||
| Q3 24 | — | $17.1M | ||
| Q2 24 | — | $17.8M | ||
| Q1 24 | $579.1M | $6.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-36.2M | $-1.3M |
| Free Cash FlowOCF − Capex | $-36.2M | — |
| FCF MarginFCF / Revenue | -1560.0% | — |
| Capex IntensityCapex / Revenue | 0.3% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-124.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-36.2M | $-1.3M | ||
| Q3 25 | $-38.9M | $-1.8M | ||
| Q2 25 | $-28.0M | $-511.0K | ||
| Q1 25 | — | $-1.1M | ||
| Q4 24 | $-20.7M | $-415.0K | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | $-1.5M | ||
| Q1 24 | $-26.0M | $-1.0M |
| Q4 25 | $-36.2M | — | ||
| Q3 25 | $-39.0M | — | ||
| Q2 25 | $-28.0M | — | ||
| Q1 25 | — | $-1.1M | ||
| Q4 24 | $-20.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-26.0M | — |
| Q4 25 | -1560.0% | — | ||
| Q3 25 | -2340.4% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -278.1% | ||
| Q4 24 | -4577.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -4919.5% | — |
| Q4 25 | 0.3% | 0.0% | ||
| Q3 25 | 5.8% | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | 45.8% | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.3% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
